pharmaceutical
[용어속성] Term
Evaluation of the efficacy and safety of Melatonin in moderately ill patients with COVID-19: A structured summary of a study protocol for a randomized controlled trial
중등도의 COVID-19 환자에서 멜라토닌의 효능 및 안전성 평가: 무작위 대조 시험을 위한 연구 프로토콜의 구조화된 요약
Letter
[키워드] 1:1
acute respiratory syndrome
Adverse drug reaction
Adverse drug reactions
alcohol
All study participants
allergy
allocation sequence
Alpha
anticipated
Antiviral
Arm
ARMS
assigned
Bandar Abbas
blinded
Blinding
block randomization
Breastfeeding
C-reactive protein
Chain Reaction
chronic hepatitis
cirrhosis
clinical
clinical symptom
Clinical symptoms
clinical trials
Clinicians
Computed tomography
conducted
Confirmed
Control
control group
Corticosteroids
COVID-19
COVID-19 pneumonia
criteria
Critical
Department
Depression
diabetes
Diabetes Mellitus
Diagnosis
Diseases
dissemination
dose
double-blind
drug
drugs
education
Efficacy and safety
element
evaluate
exclusion criteria
faculty
feature
generate
Hepatitis
history
Hospitalization
Hospitalized
hypertension
IL-1β
IL-6
ill patient
IMPROVE
incidence
inclusion criteria
inflammatory parameter
inflammatory parameters
Inflammatory responses
Informed consent
interleukin
interleukin-1β
Iran
liver diseases
Medical Sciences
Medicines
melatonin
Ministry of Health
number
Nurses
objective
outcome
oxygen
oxygen saturation
parallel-group
participant
Participants
Patient
patients
patients randomized
pharmaceutical
Pharmacy
Placebo
placebo-controlled clinical trial
Pneumonia
polymerase chain
polymerase chain reaction
polymerase chain reaction)
positive
Pregnancy
Primary outcome
Primary outcomes
protocol
random
randomization
Randomized
Randomized controlled trial
regimen
Registered
registration date
registration number
registry
Research
respiratory
Sample size
SARS-CoV-2
screened
secondary outcome
Secondary outcomes
Seizure
serum
Seven
Severe acute respiratory syndrome
single-center
standard treatment
status
Study protocol
the Faculty
therapeutic
treatment arm
trial protocol
Trial registration
Tumor
tumor necrosis
tumor necrosis factor
tumor necrosis factor-alpha
two group
two groups
underlying diseases
university
Version
Warfarin
web-based system
website
X-ray
[DOI] 10.1186/s13063-020-04737-w PMC 바로가기 [Article Type] Letter
[DOI] 10.1186/s13063-020-04737-w PMC 바로가기 [Article Type] Letter
The Efficacy of Famotidine in improvement of outcomes in Hospitalized COVID-19 Patients: A structured summary of a study protocol for a randomised controlled trial
입원한 COVID-19 환자의 결과 개선에 대한 파모티딘의 효능: 무작위 대조 시험을 위한 연구 프로토콜의 구조화된 요약
Letter
[키워드] Alanine
Alanine transaminase
alcoholism
All participant
All participants
allergies
allergy
allocation
approved
ARMS
aspartate
Aspartate transaminase
assigned
assumption
Bandar Abba
Bandar Abbas
baseline
Blinding
block randomization
blood count
Care
Chronic kidney disease
clearance
clinical
clinical trial
clinical trials
code
Committee
company
comparator
Comparator group
complete blood count
concealed
control group
control groups
COVID-19
COVID-19 patient
COVID-19 patients
creatinine
creatinine clearance
criteria
Dasatinib
dialysis
discharge
dissemination
dosage
drug therapy
electrocardiogram
element
eligibility criteria
End-stage renal disease
ethics committee
Evidence
evidence of
excluded
expected
Famotidine
G6PD
Glucose
Glucose 6 phosphate
grouping
groups
Hepatitis
hepatitis C
Hospitalized
Immunocompromised
Immunocompromised patients
Infection
Intervention
Kidney disease
Lactate
lactate dehydrogenase
lead
limit
Liver disease
Local
lung infiltration
maximum
Medical Science
Medical Sciences
moderate
need for dialysis
Neratinib
normal limit
number
objective
online tool
oral contraceptives
outcome
outcome assessor
outcome assessors
oxygen
oxygen saturation
Ozanimod
participant
Patient
patients
patients with COVID-19
Pazopanib
PCR test
pharmaceutical
Pharmaceutical Company
phosphate
Placebo
placebo-controlled
porphyria
positive
Pregnancy
protocol
psoriasis
random
randomisation
randomised
randomised controlled trial
randomized clinical trial
Randomly
randomly divided
receive
recruitment
Registered
registry
renal
renal disease
renal failure
reported
Research question
researcher
respiration rate
responsible
Rilpivirine
Sample size
sample size calculation
sequence
sequence information
single-blind
Siponimod
Standard
study drug
Study protocol
subject
submitted
technology
temperature
the ethics committee
therapy
title
Tizanidine
transaminase
Treatment
treatment group
Treatment protocol
treatment protocols
Trial registration
two group
two groups
university
Version
website
were measured
written consent
[DOI] 10.1186/s13063-020-04773-6 PMC 바로가기 [Article Type] Letter
[DOI] 10.1186/s13063-020-04773-6 PMC 바로가기 [Article Type] Letter
May Mangafodipir or Other SOD Mimetics Contribute to Better Care in COVID-19 Patients?
Viewpoint
[키워드] accompanied
acute respiratory syndrome
administration
Affect
aggregation
appear
approach
Better
Cardiopulmonary
characterized
chronic obstructive
clinical settings
clinical trial
Compound
Concentration
contrast agent
coronavirus
COVID-19
COVID-19 patient
disease
dismutase
double-blind
Efficacy
Endothelium
enzyme
expected
form
GC4419
inactivation
Inc
Inflammation
Inflammatory
Inflammatory response
inhibit
kill
life-threatening
low molecular weight
lung epithelial cell
magnetic resonance imaging
mangafodipir
manganese
manuscript
MnSOD
MnSOD-mimetic
MRI
Neutralizing
Nitrate
nitric oxide
organ
organs
Other
Patient
patients
pharmaceutical
pharmacological
Platelet
PROTECT
pulmonary disease
Randomized
resulting
risk
SARS-CoV-2
SARS-CoV-2 patient
SARS-CoV-2 patients
shown
submission
Superoxide
sustained
thrombosis
Treatment
vasoconstriction
widespread
[DOI] 10.3390/antiox9100971 PMC 바로가기 [Article Type] Viewpoint
[DOI] 10.3390/antiox9100971 PMC 바로가기 [Article Type] Viewpoint
Effects of Ginger on clinical manifestations and paraclinical features of patients with Severe Acute Respiratory Syndrome due to COVID-19: A structured summary of a study protocol for a randomized controlled trial
Letter
[키워드] 1:1
All study participants
allergy
antiarrhythmic drug
anticipated
Arm
assigned
Bandar Abbas
blinded
block randomization
Breastfeeding
C-reactive protein
clinical
clinical manifestation
Clinical symptoms
clinical trial
Clinicians
company
Confirmed
Control
Corticosteroids
COVID-19
criteria
Critical
Department
Diagnosis
disease
Diseases
disorder
dissemination
diuretics
dose
double-blind
dry cough
education
Effect
element
Eligible participants
exclusion criteria
feature
Features
Fever
GI symptom
GI symptoms
ginger
history
hypertension
incidence
Inclusion
inhibitor
investigator
Iran
liver
lung involvement
lymphocytopenia
Ministry of Health
number
Nurses
objective
outcome
parallel group
participant
Patient
patients
pharmaceutical
placebo tablet
placebo-controlled clinical trial
Pneumonia
polymerase chain
Primary outcome
protocol
randomization
Randomized
Randomized controlled trial
regimen
Registered
registration date
registry
renal
Research
respiratory
Sample size
SARS-CoV-2
secondary outcome
selective
Serious Adverse Event
serotonin reuptake inhibitor
Seven
single center
standard treatment
status
Study protocol
Tablet
therapeutic
Thyroid
time
tiredness
treatment arm
two group
Version
web-based system
website
[DOI] 10.1186/s13063-020-04765-6 PMC 바로가기 [Article Type] Letter
[DOI] 10.1186/s13063-020-04765-6 PMC 바로가기 [Article Type] Letter
Computational Evaluation of the Inhibition Efficacies of HIV Antivirals on SARS-CoV-2 (COVID-19) Protease and Identification of 3D Pharmacophore and Hit Compounds
Research Article
[키워드] acute respiratory syndrome
analysed
anti-HIV drug
antiviral drugs
AutoDock
binding affinity
binding score
carried
classification
Compound
compounds
Computational study
coronavirus
coronavirus disease
COVID-19
derivation
Discovery Studio
docked
docking study
drug
Efficacy
eight
evaluate
evaluated
Health practitioner
HIV
HIV treatment
hydrophilic
identification
identify
In silico methods
in vivo
inhibit
inhibition
Interaction
majority
medication
molecular
Novel coronavirus
parameters
Patient
performed
pharmaceutical
pharmacophore
protease
Protease inhibitor
Protein Data Bank
reported
researcher
Ritonavir
SARS-CoV-2
SARS-CoV-2 protease
spread of COVID-19
Structure
the SARS-CoV-2
these compound
these compounds
treat
Vaccine
was obtained
web server
X-ray crystallographic structure
[DOI] 10.1155/2020/8818008 PMC 바로가기 [Article Type] Research Article
[DOI] 10.1155/2020/8818008 PMC 바로가기 [Article Type] Research Article
Characterizing the Impact of Social Inequality on COVID-19 Propagation in Developing Countries
Mathematics
[키워드] absence
Affect
Brazil
country
COVID-19
COVID-19~propagation
deep
Developing
developing countries
Effect
Epidemic
fatality
Health
health condition
heterogeneity
hygiene
Impact
inequality
measure
Measures
mechanism
Mortality
Non-pharmaceutical interventions
number of infected
outbreak
pandemic
pharmaceutical
Pharmaceutical interventions
Population
predict
Propagation
SEIR
social distancing
social inequality
Spread
virus
with COVID-19
[DOI] 10.1109/ACCESS.2020.3024910 PMC 바로가기 [Article Type] Mathematics
[DOI] 10.1109/ACCESS.2020.3024910 PMC 바로가기 [Article Type] Mathematics
Effects of Licorice on clinical symptoms and laboratory signs in moderately ill patients with pneumonia from COVID-19: A structured summary of a study protocol for a randomized controlled trial
Letter
[키워드] 1:1
Adverse reaction
age
allergy
Anti-inflammatory
Antibody test
anticipated
antiviral therapy
assigned
Bandar Abba
Bandar Abbas
Blinding
Breastfeeding
C-reactive protein
Chest computed tomography
chronic heart disease
clinical
clinical study
clinical symptom
Clinical symptoms
clinical trial
company
conducted
Confirmed
Control
control group
Corticosteroids
COVID-19
criteria
Critical
diagnosis of SARS-CoV-2
Diseases
disorders
dissemination
diuretics
dose
drugs
dry cough
education
Effect
element
evaluated
feature
Features
female patient
Fever
glycyrrhiza
history
hospital
Hospitalization
hypertension
ill patient
incidence
Infection
inhibitor
intervention group
Iran
Laboratory
Laboratory signs
licorice
liquorice
liver
lymphocytopenia
male
Medical Sciences
Ministry of Health
Moderate COVID-19
number
objective
Open-label
outcome
parallel-group
participant
Patient
pharmaceutical
Placebo
Pneumonia
polymerase chain
Primary outcome
protocol
random
randomization
randomize
Randomized
Randomized controlled trial
regimen
Registered
registry
renal
Sample size
screened
secondary outcome
selective
serotonin reuptake inhibitor
Seven
single-center
standard treatment
status
Study protocol
therapeutic
Thyroid
time
tiredness
Treatment
treatment arm
Trial
university
Version
website
X-ray
[DOI] 10.1186/s13063-020-04706-3 PMC 바로가기 [Article Type] Letter
[DOI] 10.1186/s13063-020-04706-3 PMC 바로가기 [Article Type] Letter
Risk of hydroxychloroquine alone and in combination with azithromycin in the treatment of rheumatoid arthritis: a multinational, retrospective study
Articles
[키워드] addition
adverse event
angina
appear
authorisation
calibrated
case sery
chest pain
cohort study
Combination
Cox model
Denmark
Department
determine
development
electronic medical record
Emergency use
estimate
European
Federation
finding
foundation
funding
Germany
hazard ratio
heart failure
Horizon
HRs
Hydroxychloroquine
hydroxychloroquine plus azithromycin
hydroxychloroquine treatment
increase
increased risk
initiative
Innovation
IQVIA
janssen
Japan
less
Medical Research Council
Medicine
Ministry of Health
Mortality
negative control
Netherlands
NIHR
Older
outcome
Oxford
partnership
Patient
patients with COVID-19
pharmaceutical
Pneumonia
populations
Propensity score
Research
Retrospective study
rheumatoid arthritis
risk
routine care
severe adverse event
Singapore
Spain
Stratification
sulfasalazine
training
treat
Treatment
USA
use of hydroxychloroquine
veteran
Welfare
were used
[DOI] 10.1016/S2665-9913(20)30276-9 PMC 바로가기 [Article Type] Articles
[DOI] 10.1016/S2665-9913(20)30276-9 PMC 바로가기 [Article Type] Articles
Virtual screening, molecular docking studies and DFT calculations of FDA approved compounds similar to the non-nucleoside reverse transcriptase inhibitor (NNRTI) efavirenz
Article
[키워드] acute respiratory syndrome
approved
calculated
Compound
compounds
coronavirus
COVID-19
COVID-19 disease
COVID-19 infection
docking
drug-likeness
efavirenz
FDA
FDA approved drug
FIVE
functional
highest
HIS163
His41
HIV
inhibitor
interacting residue
Interaction
lowest
molecular
Molecular docking study
NNRTI
performed
pharmaceutical
Pharmaceutical chemistry
Phe140
podophyllotoxin
protease
protease inhibitors
SARS-CoV-2
selected
Theoretical chemistry
transcriptase
treat
Virtual screening
virus
worldwide pandemic
[DOI] 10.1016/j.heliyon.2020.e04642 PMC 바로가기 [Article Type] Article
[DOI] 10.1016/j.heliyon.2020.e04642 PMC 바로가기 [Article Type] Article